Onco-Innovations Advances Nanoparticle PNKP Inhibitor for DNA Damage Response Cancer Therapies

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself in the expanding DNA Damage Response (DDR) oncology market through development of ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to a BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030.

The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development across multiple cancer indications. The editorial noted that ONC010 has demonstrated encouraging preclinical results, including extended survival and tumor growth reduction in colorectal cancer models, while the company advances manufacturing, formulation and IND-enabling activities through partnerships with Dalton Pharma Services and Nucro-Technics.

Onco-Innovations also acquired Inka Health Corp., whose SynoGraph causal AI platform is designed to support patient stratification and clinical trial design as the company prepares for anticipated first-in-human studies. The report highlighted continued innovation across the biotechnology sector, citing recent regulatory and clinical milestones reported by Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD).

For more details, visit the full press release at https://ibn.fm/cFCop. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Onco-Innovations Advances Nanoparticle PNKP Inhibitor for DNA Damage Response Cancer Therapies.

The post Onco-Innovations Advances Nanoparticle PNKP Inhibitor for DNA Damage Response Cancer Therapies appeared first on citybuzz.